Vaginal oestrogen therapy in women with hormone-sensitive breast cancer

Vaginal atrophy is a common problem in women who have previously been treated for breast cancer. Endocrine therapy plays an essential role in the treatment of breast cancer. Systemic hormonal treatment is contraindicated. Topical oestrogens are an effective treatment for vaginal atrophy, but are poo...

Full description

Saved in:
Bibliographic Details
Published inUgeskrift for læger Vol. 173; no. 9; p. 648
Main Authors Bak, Ann Mosegaard, Laursen, Britt Elmedal, Rungby, Jørgen, Brock, Birgitte
Format Journal Article
LanguageDanish
Published Denmark 28.02.2011
Subjects
Administration, Intravaginal
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Aromatase Inhibitors - adverse effects
Aromatase Inhibitors - therapeutic use
Atrophy
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Contraindications
Estrogen Antagonists - adverse effects
Estrogen Antagonists - therapeutic use
Estrogen Replacement Therapy
Estrogens - administration & dosage
Female
Humans
Menopause
Neoplasm Recurrence, Local - chemically induced
Tamoxifen - adverse effects
Tamoxifen - therapeutic use
Vagina - drug effects
Vagina - metabolism
Vagina - pathology
Online AccessGet more information

Cover

More Information
Summary:Vaginal atrophy is a common problem in women who have previously been treated for breast cancer. Endocrine therapy plays an essential role in the treatment of breast cancer. Systemic hormonal treatment is contraindicated. Topical oestrogens are an effective treatment for vaginal atrophy, but are poorly studied in this group of patients. Physicians are reluctant to recommend it because of the potential increase in the risk of recurrence. The sparse data available suggest that vaginal oestrogen may be used relatively safely by women who are in tamoxifen treatment, but should not be used by women who receive aromatase inhibitor treatment.
ISSN:1603-6824